number
antivir
therapi
evolv
may
effect
administ
treat
respiratori
viral
diseas
thu
provid
physician
rang
therapi
altern
includ
amantadin
hay
et
al
neuraminidas
inhibitor
calfe
hayden
nucleosid
analogu
fyfe
et
al
hruska
et
al
one
hand
therapi
limit
effect
hand
sideeffect
system
toxic
may
limit
applic
particularli
paediatr
geriatr
compromis
patient
reusser
cassadi
whitley
bacon
et
al
hayden
et
al
janai
et
al
englund
et
al
result
great
interest
develop
efficaci
antivir
compound
herbal
origin
low
toxic
well
toler
herbal
medicin
plant
extract
wide
use
tradit
medicin
de
clercq
due
antimicrobi
antivir
effect
interestingli
speci
studi
show
signific
antivir
activ
vitro
che
innumer
potenti
use
medicin
plant
herb
wait
evalu
exploit
therapeut
applic
genet
function
divers
viru
famili
jassim
naji
sever
hundr
alreadi
investig
plant
herb
speci
potenti
novel
antivir
agent
jassim
naji
howev
major
speci
studi
far
systemat
investig
activ
broad
panel
virus
still
remain
done
summerfield
et
al
describ
acanthospermum
hispidum
summerfield
et
al
activ
anim
pathogen
herp
virus
pseudorabiesviru
prv
bovin
herpesviru
recent
et
al
abl
show
antivir
activ
extract
eleutherococcu
senticosu
human
rhinoviru
hrv
human
respiratori
syncyti
viru
rsv
influenza
viru
discuss
rnaviru
specif
reactiv
addit
broad
antivir
activ
see
front
matter
elsevi
gmbh
right
reserv
homeopath
prepar
grippheel
demonstr
act
human
herpesviru
human
adenoviru
hav
human
parainfluenza
viru
human
coxsackieviru
influenza
viru
hrv
rsv
might
base
induct
type
interferon
glatthaar
respect
substanc
nevertheless
detail
inform
yet
avail
exact
mode
antivir
action
plant
extract
recent
micha
et
al
investig
influenc
standardis
extract
pelargonium
sidoid
ep
market
herbal
medicin
product
umckaloabo
treatment
acut
bronchiti
replic
panel
respiratori
virus
author
abl
show
ep
concentr
gml
interf
replic
season
influenza
viru
strain
respiratori
syncyti
viru
human
coronaviru
parainfluenza
viru
coxsackieviru
affect
replic
highli
pathogen
avian
influenza
viru
adenoviru
rhinoviru
vitro
antivir
potenti
herbal
medicin
product
sinupret
wide
use
phytotherapeut
treatment
acut
chronic
rhinosinus
common
cold
infect
upper
respiratori
tract
observ
glatthaar
christoffel
author
could
show
sinupret
drop
extract
constitut
combin
ie
extract
verbena
herb
primula
flower
reduc
spread
three
virus
influenza
respiratori
syncyti
viru
parainfluenza
type
antivir
effect
sinupret
vivo
could
demonstr
murin
viru
model
sendai
viru
surviv
time
mice
could
increas
sinupret
tablet
therapeut
et
al
sinupret
drop
given
prophylact
schmolz
et
al
present
studi
antivir
effect
two
sinupret
prepar
oral
drop
hereinaft
refer
oral
drop
sinupret
dri
extract
hereinaft
refer
dri
extract
investig
two
herbal
extract
gentian
root
primula
flower
elder
flower
sorrel
herb
verbena
herb
test
broad
panel
virus
respons
infect
upper
respiratori
tract
object
studi
evalu
vitro
antivir
characterist
sinupret
prepar
human
pathogen
rnaand
dnavirus
commerci
avail
sinupret
suppli
manufactur
ethanol
solut
vv
sinupret
oral
drop
g
oral
drop
contain
g
aqueousethanol
extract
extract
agent
ethanol
vv
drugextract
ratio
gentiana
radix
primula
flo
cum
calycibu
sambuci
flo
rumici
herba
sorrel
verbena
herba
fix
ratio
concentr
oral
drop
given
equival
dri
extract
use
known
drugextract
ratio
addit
sinupret
test
nativ
dri
extract
special
extract
bno
dri
extract
deliv
manufactur
composit
ident
drop
regard
herb
dri
extract
prepar
ethanol
extract
agent
vv
final
drugextract
ratio
use
test
dri
extract
prepar
stock
solut
mgml
ethanol
mgml
ethanol
repetit
flua
pflua
qualiti
herbal
drug
start
materi
specifi
accord
relev
emaguidelin
herbal
medicin
product
prepar
manufactur
valid
product
process
accord
gmp
comprehens
specif
standardis
product
process
guarante
high
batchtobatch
consist
experi
stock
solut
test
substanc
dilut
cellcultur
medium
ad
cell
cultur
respect
test
viru
strain
except
posit
control
includ
singl
concentr
close
ic
ribavirin
virazol
icn
pharmaceut
frankfurt
germani
gml
use
infect
rsv
hruska
et
al
amantadin
amantadin
hydrochlorid
ratiopharm
ulm
germani
use
infect
human
porcin
influenza
viru
hay
et
al
gml
gml
respect
laboratori
intern
standard
use
posit
control
para
hrv
adeno
gml
gml
gml
respect
effect
refer
substanc
confirm
test
refer
substanc
show
reduct
viral
plaqu
flua
pflua
para
hrv
cpe
adeno
human
rhinoviru
b
subtyp
hrv
obtain
institut
virolog
friedrichschillerunivers
jena
germani
influenza
chile
viru
flua
respiratori
syncyti
viru
strain
long
rsv
parainfluenza
type
viru
para
cocksackieviru
subtyp
adenoviru
c
subtyp
adeno
obtain
depart
medic
virolog
epidemiolog
viru
diseas
hygien
institut
univers
germani
porcin
influenza
pflua
obtain
nation
institut
biolog
standard
control
nibsc
hertfordshir
uk
virus
identifi
characteris
panel
monoclon
antibodi
biowhittack
product
walkersvil
md
rsv
para
adeno
propag
human
epitheli
cell
hrv
hela
cell
buffalogreenmonkey
bgm
cell
hanksearl
minim
essenti
medium
mem
contain
foetal
calf
serum
mm
mgcl
mm
lglutamin
uml
penicillin
mgml
streptomycin
flua
pflua
grown
madindarbycaninekidney
mdck
cell
serumfre
mem
contain
gml
trypsin
mm
lglutamin
uml
penicillin
mgml
streptomycin
order
determin
viru
titr
respect
cell
incub
serial
dilut
serumfre
viru
stock
solut
h
c
remov
viru
inoculum
cell
cultur
overlaid
respect
virusspecif
medium
contain
agaros
carboxymethylcellulos
analys
plaqu
plaqu
form
unit
pfu
cytopathogen
effect
cpe
perform
day
later
respect
viru
titr
calcul
pfuml
method
mean
infecti
concentr
log
tcid
ml
plaqu
assay
assay
cpe
perform
mdck
bgm
helacel
cultur
use
standard
procedur
detect
infecti
particl
quantif
rsvand
adeno
antigen
enzym
immunoassay
virionserion
tabl
cytotox
sinupret
prepar
oral
drop
dri
extract
inhibitori
concentr
gml
cytotox
respect
cell
mdck
hela
bgm
cultiv
differ
concentr
sinupret
prepar
rang
gml
correspond
ethanol
ethanol
rang
solut
quantifi
use
mttassay
rel
cytotox
sinupret
prepar
standardis
medium
control
repres
viabil
tabl
show
concentrationdepend
intox
sinupret
calcul
inhibitori
concentr
data
repres
four
replic
concentr
use
addit
test
flua
pflua
germani
merlin
diagnostika
gmbh
bornheimhersel
germani
use
analys
vitro
cytotox
sinupret
prepar
perform
physiolog
activ
cell
enzymat
assay
mttassay
mosmann
capabl
quantifi
activ
mitochondri
enzym
activ
divid
cell
show
direct
correl
viabil
enzym
activ
addit
cytotox
test
substanc
respect
cell
monitor
microscop
examin
cell
cultur
alter
cell
morpholog
determin
limit
toxic
concentr
mdck
bgm
hela
cell
cultiv
growth
period
togeth
differ
dilut
log
gml
gml
test
substanc
c
co
least
day
respect
cell
cultur
media
without
test
compon
use
control
medium
control
plaquereduct
assay
pfu
cytopathogen
effect
cpe
immunoassay
elisa
antivir
activ
oral
drop
dri
extract
measur
plaquereduct
assay
cooper
plaqu
form
unit
pfu
flua
pflua
para
rsv
hrv
analys
cytopathogen
effect
cpe
adeno
cell
monolay
infect
multipl
infect
moi
flua
para
rsv
hrv
pflua
adeno
without
presenc
differ
nontox
dilut
test
substanc
rang
gml
addit
respect
ethanol
control
cell
infect
h
c
cell
monolay
wash
overlay
medium
contain
differ
concentr
test
substanc
gml
subsequ
infect
cell
cultur
cultiv
three
day
mdck
flua
bgm
four
day
hela
hrv
five
day
mdck
pflua
para
six
day
rsv
seven
day
adeno
lesion
visibl
cell
monolay
plaqu
cpe
viru
infect
control
group
cultiv
medium
alon
time
point
cell
fix
paraformaldehyd
remain
cell
monolay
stain
crystal
violet
solut
nonstain
lesion
cell
monolay
plaqu
cpe
quantifi
employ
optic
evalu
system
case
rsv
adeno
addit
analysi
lesion
plaqu
cpe
amount
newli
synthesis
viru
determin
enzym
immunoassay
elisa
quantif
antivir
activ
carri
either
analys
number
plaqu
pfu
flua
para
hrv
rsv
pflua
lesion
viral
cpe
adeno
amount
viral
protein
elisa
adeno
rsv
calcul
base
mean
valu
two
cpe
adeno
pfu
rsv
pflua
repetit
flua
three
pfu
flua
para
hrv
elisa
adeno
rsv
replic
deriv
two
independ
experi
ethanol
control
valu
differ
significantli
water
control
valu
normalis
mean
valu
correspond
cell
cultur
medium
control
concentr
oral
drop
calcul
equival
dri
extract
concentr
base
known
drugextract
ratio
result
nontreat
viru
control
group
defin
infect
inhibit
vitro
effect
substanc
standardis
rel
inhibitori
effect
calcul
ec
r
signific
valu
perform
nonlinear
regress
use
graphpad
prism
log
agonist
vs
normalis
respons
variabl
slope
function
integr
comparison
calcul
ec
valu
extra
sum
squar
ftest
graphpad
prism
version
window
graphpad
softwar
inc
case
maxim
viru
inhibit
less
appar
ec
valu
given
gml
gml
respect
cytotox
result
sinupret
prepar
present
tabl
mttassay
demonstr
low
toxic
plant
extract
inhibitori
concentr
ic
ethanol
plant
composit
oral
drop
calcul
sever
experi
less
gml
ie
gml
mdck
cell
gml
cell
gml
hela
cell
gml
bgm
cell
ic
dri
extract
prepar
compar
oral
drop
toxic
limit
cell
line
higher
gml
test
substancerel
metabol
impair
could
detect
group
concentr
gml
ethanol
control
use
assay
toxic
final
concentr
vv
show
slightli
reduc
metabol
dilut
less
vv
ethanol
cell
cultur
medium
show
cytotox
effect
consequ
prepar
oral
drop
use
evalu
antivir
activ
adjust
ethanol
content
less
vv
correspond
highest
concentr
gml
accordingli
sinupret
dri
extract
adjust
concentr
gml
maximum
ethanol
content
vv
highest
concentr
use
antivir
test
except
addit
test
flua
pflua
gml
maximum
ethanol
content
use
highest
concentr
antivir
activ
yaxi
viru
inhibit
test
candid
xaxi
concentr
gml
determin
plaquereduct
assay
pfu
flua
para
rsv
hrv
analys
cytopathogen
effect
cpe
adeno
rel
inhibit
inhibit
ordin
calcul
analys
number
plaqu
lesion
viral
cpe
respect
group
standardis
viru
control
repres
infect
inhibit
posit
control
confirm
procedur
flua
gml
amantadin
inhibit
para
laboratori
standard
gml
inhibit
hrv
laboratori
standard
gml
inhibit
adeno
laboratori
standard
gml
inhibit
rsv
gml
ribavirin
inhibit
data
repres
mean
sem
two
independ
experi
two
adeno
rsv
three
flua
para
hrv
replic
star
indic
statist
signific
differ
valu
dri
extract
oral
drop
p
tabl
present
effect
concentr
reduct
viru
replic
ec
gml
treatment
addit
substanc
h
viru
infect
cell
cultur
infect
envelop
rna
virus
flua
para
sinupret
prepar
show
clear
concentrationdepend
effect
viru
replic
vitro
fig
regard
influenc
fluaspecif
viru
plaqu
oral
drop
open
squar
produc
reduct
highest
concentr
gml
dri
extract
close
triangl
show
compar
result
plaqu
reduct
gml
group
antivir
effect
diminish
within
two
dilut
step
demonstr
concentrationdepend
effect
compar
antivir
effect
dri
extract
pflua
flua
ec
gml
gml
respect
fig
tabl
wherea
ec
valu
oral
drop
flua
gml
fig
tabl
refer
substanc
amantadin
reduc
flua
growth
concentr
gml
pflua
growth
concentr
gml
mediumcontrol
presenc
five
descend
noncytotox
concentr
xaxi
gml
test
substanc
oral
drop
dri
extract
antivir
activ
sinupret
virus
determin
plaqu
reduct
assay
plaqu
form
unit
pfu
rsv
analys
cytopathogen
effect
cpe
adeno
open
column
quantif
amount
newli
synthesis
viru
enzym
immunoassay
elisa
stripe
column
rel
inhibit
yaxi
inhibit
calcul
analys
number
plaqu
lesion
viral
cpe
amount
viral
protein
respect
group
standardis
viru
control
repres
infect
inhibit
result
antivir
activ
rsv
shown
upper
adeno
lower
panel
posit
control
confirm
procedur
adeno
laboratori
standard
gml
cpe
elisa
inhibit
rsv
gml
ribavirin
pfu
elisa
inhibit
data
repres
mean
sem
two
independ
experi
two
pfu
cpe
three
elisa
replic
concentr
inhibit
viral
acit
nc
calcul
inhibit
maximum
concentr
least
one
prepar
lower
nt
test
p
signific
dri
extract
vs
oral
drop
rel
viru
addit
cell
differ
concentr
sinupret
ad
h
infect
left
throughout
incub
period
antivir
activ
determin
plaquereduct
assay
pfu
flua
pflua
para
rsv
hrv
analys
cytopathogen
effect
cpe
adeno
addit
rsv
adeno
data
ascertain
elisa
rel
inhibit
sinupret
standardis
viru
control
repres
infect
inhibit
tabl
show
concentrationdepend
antivir
effect
sinupret
use
therapeut
protocol
calcul
effect
concentr
data
base
mean
two
adeno
cpe
rsv
pfu
pflua
repetit
flua
three
flua
para
hrv
adeno
elisa
rsv
elisa
replic
deriv
two
independ
experi
addit
test
higher
concentr
dri
extract
use
antivir
activ
yaxi
viru
inhibit
test
candid
xaxi
concentr
gml
determin
plaquereduct
assay
pfu
flua
close
triangl
pflua
close
circl
rel
inhibit
inhibit
ordin
calcul
analys
number
plaqu
respect
group
standardis
viru
control
repres
infect
inhibit
posit
control
confirm
procedur
flua
amantadin
gml
inhibit
pflua
amantadin
gml
inhibit
data
repres
mean
sem
two
independ
experi
two
three
replic
effect
sinupret
prepar
para
infect
cell
less
promin
prepar
show
concentrationdepend
plaqu
reduct
highest
concentr
gml
oral
drop
gml
dri
extract
respect
fig
consid
concentr
respons
curv
efficaci
dri
extract
slightli
higher
oral
drop
laboratori
intern
refer
compound
inhibit
para
concentr
gml
two
nonenvelop
rna
virus
hrv
oral
drop
dri
extract
produc
signific
viral
plaqu
reduct
viru
infect
cell
bgm
cell
cultur
dri
extract
induc
viral
plaqu
reduct
gml
wherea
oral
drop
show
viral
plaqu
reduct
gml
effect
sinupret
prepar
concentrationdepend
show
compar
concentr
respons
curv
fig
ec
valu
gml
dri
extract
gml
oral
drop
tabl
oral
drop
gml
induc
dri
extract
gml
induc
concentrationdepend
inhibit
hrv
plaqu
hela
cell
cultur
fig
dri
extract
ec
gml
tendenc
p
effect
sinupret
oral
drop
ec
gml
fig
tabl
laboratori
intern
refer
compound
inhibit
hrv
concentr
gml
strongest
antivir
effect
two
sinupret
prepar
could
detect
two
human
pathogen
virus
rsv
envelop
rnaviru
adeno
nonenvelop
dnaviru
fig
tabl
highest
concentr
gml
oral
drop
induc
reduct
rsv
viru
plaqu
dri
extract
show
compar
effect
plaqu
reduct
gml
rsv
fig
data
could
confirm
rsvspecif
elisa
detect
newli
synthesis
viral
protein
reduct
oral
drop
reduct
dri
extract
fig
suppress
activ
sinupret
prepar
rsv
concentr
depend
activ
dri
extract
dilut
step
higher
p
compar
activ
oral
drop
ec
valu
gml
dri
extract
gml
oral
drop
tabl
refer
substanc
ribavirin
produc
approxim
reduct
rsv
plaqu
reduct
viru
protein
measur
elisa
concentr
gml
similar
concentrationdepend
antivir
effect
observ
nonenvelop
dna
viru
adeno
fig
highest
concentr
sinupret
prepar
reduc
adenoviru
infect
measur
cpe
assay
oral
drop
gml
dri
extract
gml
antivir
effect
could
verifi
virusspecif
elisa
oral
drop
show
dri
extract
reduct
viral
protein
product
fig
cpe
assay
well
elisa
dri
extract
activ
compar
oral
drop
fig
higher
activ
dri
extract
also
observ
p
compar
ec
valu
gml
dri
extract
gml
oral
drop
adeno
tabl
laboratori
intern
refer
compound
produc
approxim
reduct
cytopathogen
effect
cpe
adeno
reduct
viru
protein
measur
elisa
concentr
gml
summari
present
data
demonstr
prepar
sinupret
oral
drop
dri
extract
inhibit
broad
spectrum
virus
includ
envelop
well
nonenvelop
virus
dna
rna
varieti
vitro
inhibitori
effect
dri
extract
higher
compar
oral
drop
antivir
activ
two
prepar
sinupret
drop
dri
extract
wide
panel
human
pathogen
virus
caus
infect
upper
respiratori
tract
could
demonstr
prepar
show
similar
concentrationdepend
activ
higher
potenc
dri
extract
interestingli
treatment
composit
affect
virus
equal
eg
para
limit
degre
reduc
highest
concentr
sinupret
use
assay
stronger
effect
visibl
hrv
rsv
adeno
uniqu
antivir
effect
rsv
relev
activ
flua
seen
higher
concentr
dri
extract
wherea
show
stronger
effect
pflua
heterogen
activ
might
indic
specif
distinct
type
virus
clear
border
eg
activ
dna
andor
rna
virus
envelop
andor
non
envelop
virus
observ
rna
virus
rsv
without
envelop
hrv
affect
significantli
wherea
envelop
rna
virus
flua
para
well
nonenvelop
rna
virus
rather
insensit
hand
replic
dna
viru
adeno
could
significantli
suppress
test
substanc
viru
dna
viru
test
far
caus
question
whether
similar
sensit
could
also
found
dna
virus
eg
virus
belong
herpesviru
famili
herp
simplex
viru
hsv
human
cytomegaloviru
hcmv
varicella
zoster
viru
vsv
obviou
besid
activ
nonenvelop
dna
viru
common
featur
less
sensit
high
sensit
rna
virus
without
envelop
therefor
addit
experi
might
give
explan
nonselect
antivir
activ
sinupret
prepar
contrast
antivir
activ
plantderiv
substanc
often
characteris
clear
border
activ
dna
rna
virus
acanthospermum
hispidum
summerfield
et
al
describ
signific
vitro
activ
anim
pathogen
dna
virus
eg
pseudorabi
viru
prv
bovin
herpesviru
bhv
wherea
rna
virus
respons
classic
swine
fever
csf
footandmouth
diseas
fmd
impair
substanc
hand
et
al
describ
clear
activ
extract
eleutherococcu
senticosu
rna
virus
et
al
comprehens
studi
use
differ
virus
might
give
hint
mechan
antivir
activ
plantderiv
substanc
data
singl
virus
publish
eg
schnitzler
et
al
report
antivir
activ
melissa
officinali
herp
virus
schnitzler
et
al
noth
known
behaviour
dna
well
rna
virus
without
envelop
present
studi
could
shown
sinupret
produc
clear
antivir
effect
ad
tissu
cultur
directli
infect
repres
therapeut
treatment
confirm
earli
therapeut
effect
detail
analys
includ
time
cours
advanc
understand
effect
complex
viruscel
interact
viral
replic
cycl
particular
interest
could
question
possibl
inhibit
intracellular
viru
amplif
antivir
activ
test
substanc
measur
direct
effect
sinupret
viral
particl
present
data
interpret
hint
indirect
antivir
mechan
induct
type
interferon
could
respons
observ
antivir
activ
dorr
case
test
substanc
would
capabl
induc
cellular
interferon
synthesi
cell
use
propag
virus
lead
inhibit
viru
replic
howev
one
might
argu
sensit
nonsensit
virus
grown
cell
line
eg
rsv
adeno
para
cell
hand
known
type
interferon
show
differ
behaviour
differ
virus
lot
open
question
mani
approach
better
understand
sinupret
prepar
antivir
activ
sinlg
compon
possibl
synergist
effect
wagner
ulrichmerzenich
nevertheless
data
demonstr
antivir
effect
two
prepar
sinupret
dri
extract
oral
drop
broad
panel
virus
